hydroxychloroquine has been researched along with Autoimmune Diseases in 66 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the chronic autoimmune urticaria study and evaluation was to evaluate the efficacy of hydroxychloroquine in patients with chronic idiopathic urticaria." | 9.11 | Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. ( Bonfield, J; Boyle, MJ; Dobson, P; Loewenthal, M; Reeves, GE, 2004) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 8.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| "Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases." | 8.93 | [Hydroxychloroquine for autoimmune diseases]. ( Danza, Á; Goñi, M; Graña, D; Ruiz-Irastorza, G; Vargas, A, 2016) |
| " Secondly, we estimated the prevalence of AVB among mothers with anti-Ro/La antibodies and examined the relationship of those fetal AVB with mother's use of hydroxychloroquine during pregnancy." | 7.91 | Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. ( Catoggio, LJ; Mollerach, FB; Rosa, J; Scolnik, M; Soriano, ER, 2019) |
| "Hydroxychloroquine has antithrombotic, cardiovascular, antimicrobial and antineoplastic effects, making it a potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy and thrombotic events." | 6.58 | New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. ( Casian, A; D'Cruz, DP; Sangle, SR, 2018) |
| "Hydroxychloroquine (HCQ) is an effective immunomodulatory drug which is widely used in treatment of autoimmune disorders." | 5.72 | A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo. ( Darchini-Maragheh, E; Fathi-Najafi, S; Layegh, P; Meshkat, M; Rahsepar, S; Sazgarnia, S; Sepehr, V, 2022) |
| "The aim of the chronic autoimmune urticaria study and evaluation was to evaluate the efficacy of hydroxychloroquine in patients with chronic idiopathic urticaria." | 5.11 | Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. ( Bonfield, J; Boyle, MJ; Dobson, P; Loewenthal, M; Reeves, GE, 2004) |
| "The objective of this meta-analysis was to determine whether gestational use of hydroxychloroquine (HCQ) for autoimmune disorders leads to an increase in the risk for adverse pregnancy outcomes." | 4.93 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. ( Kaplan, YC; Koren, G; Nickel, C; Ozsarfati, J, 2016) |
| " IFN-α (and more recently pegylated IFN-α) when administered as a component of the combined (IFN-α + ribavirin) anti-HCV therapy can promote the appearance or the worsening of several autoimmune HCV-related disorders, including arthritis." | 4.90 | An update on the management of hepatitis C virus-related arthritis. ( D'Amico, E; D'Angelo, S; Gilio, M; Leccese, P; Olivieri, I; Palazzi, C, 2014) |
| "The aim of this study is to measure retinal vessel density and flow rate area by optical coherence tomography angiography (OCTA) in patients with autoimmune diseases taking hydroxychloroquine (HCQ)." | 4.31 | Optical coherence tomography angiography parameters in patients taking hydroxychloroquine therapy. ( Dačić, B; Dijana, R; Kovačević, IM; Marić, G; Stanojlović, S; Vasilijević, JB, 2023) |
| " Secondly, we estimated the prevalence of AVB among mothers with anti-Ro/La antibodies and examined the relationship of those fetal AVB with mother's use of hydroxychloroquine during pregnancy." | 3.91 | Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. ( Catoggio, LJ; Mollerach, FB; Rosa, J; Scolnik, M; Soriano, ER, 2019) |
| " Subcutaneous administration of methotrexate was more effective than the oral administration at the same dosage in patients suffering from active rheumatoid arthritis." | 3.74 | [What's new in internal medicine?]. ( Francès, C, 2008) |
| "Chronic ulcerative stomatitis (CUS) is a rare disease of the mucous membranes with characteristics similar to other autoimmune diseases." | 2.82 | Clinical and immunological features of chronic ulcerative stomatitis: A systematic review. ( Palma, VM; Rados, PV; Schroeder, FMM; Visioli, F, 2022) |
| "Hydroxychloroquine has antithrombotic, cardiovascular, antimicrobial and antineoplastic effects, making it a potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy and thrombotic events." | 2.58 | New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. ( Casian, A; D'Cruz, DP; Sangle, SR, 2018) |
| " Although these agents have largely revolutionized the treatment of the systemic autoimmune diseases, adverse reactions, which can be serious and life threatening, to the various immunosuppressive agents used in the treatment of CTD can occur." | 2.46 | Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. ( Baughman, R; Decker, C; Meyer, KC, 2010) |
| "In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs)." | 1.72 | COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. ( Agarwal, V; Aggarwal, R; Cavagna, L; Chatterjee, T; Chinoy, H; Day, J; Distler, O; Gaur, PS; Gheita, T; Gil-Vila, A; Gonzalez, RA; Gracia-Ramos, AE; Gupta, L; Joshi, M; Kardes, S; Kim, M; Knitza, J; Kuwana, M; Lilleker, JB; Makol, A; Milchert, M; Nikiphorou, E; Nune, A; Parodis, I; Ravichandran, N; Saavedra, MA; Salim, B; Selva-O'Callaghan, A; Sen, P; Shinjo, SK; Tan, AL; Velikova, T; Ziade, N, 2022) |
| "Hydroxychloroquine (HCQ) is an effective immunomodulatory drug which is widely used in treatment of autoimmune disorders." | 1.72 | A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo. ( Darchini-Maragheh, E; Fathi-Najafi, S; Layegh, P; Meshkat, M; Rahsepar, S; Sazgarnia, S; Sepehr, V, 2022) |
| "To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study." | 1.62 | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. ( Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N, 2021) |
| "Autoimmune myelofibrosis is a distinct clinicopathological entity that occurs with autoimmune disorders." | 1.51 | Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus. ( Belfeki, N; Declerck, D; Diamantis, S; Shankarasivam, G, 2019) |
| "Hydroxychloroquine is a valuable treatment for morphea because of its high response rate and low rate of adverse effects; however, prospective studies are needed to determine its true efficacy." | 1.51 | Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. ( Blixt, EK; Drage, LA; El-Azhary, RA; Kumar, AB; Wetter, DA, 2019) |
| " Adhering to careful weight-based dosing can significantly reduce the risk of this adverse event and is recommended in recent guidelines." | 1.46 | Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. ( Gianfrancesco, MA; Haserodt, S; Izadi, Z; Jafri, K; Schmajuk, G; Shiboski, S; Sirota, M; Trupin, L; Yazdany, J, 2017) |
| "CHI is associated with high recurrence rate and the combined regimen seems to be necessary, in particular, in the presence of previous intrauterine death." | 1.42 | Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| " In at least one patient, the technique was able to detect the early onset of Plaquenil toxicity followed by reversal of the toxic effects after the medication was discontinued." | 1.35 | Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity. ( Lyons, JS; Severns, ML, 2009) |
| "Hydroxychloroquine alone was given in 4 and was effective in 3." | 1.33 | Chronic inflammation of the vagina: treatment and relationship to autoimmunity. ( Thomson, JC, 2005) |
| "In untreated rheumatoid arthritis 20% of the patients has a EOG Lp/Dt ratio lower than the lower 5% limit calculated for normal patients." | 1.27 | The EOG in rheumatoid arthritis. ( Broekhuyse, RM; Pinckers, A, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.58) | 18.7374 |
| 1990's | 4 (6.06) | 18.2507 |
| 2000's | 11 (16.67) | 29.6817 |
| 2010's | 24 (36.36) | 24.3611 |
| 2020's | 22 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Xiao, R | 1 |
| Zeng, R | 1 |
| He, E | 1 |
| Zhang, A | 1 |
| Schroeder, FMM | 1 |
| Palma, VM | 1 |
| Rados, PV | 1 |
| Visioli, F | 1 |
| Gil-Vila, A | 1 |
| Ravichandran, N | 1 |
| Selva-O'Callaghan, A | 1 |
| Sen, P | 1 |
| Nune, A | 1 |
| Gaur, PS | 1 |
| Gonzalez, RA | 1 |
| Lilleker, JB | 1 |
| Joshi, M | 1 |
| Agarwal, V | 2 |
| Kardes, S | 1 |
| Kim, M | 1 |
| Day, J | 1 |
| Makol, A | 1 |
| Milchert, M | 1 |
| Gheita, T | 1 |
| Salim, B | 1 |
| Velikova, T | 1 |
| Gracia-Ramos, AE | 1 |
| Parodis, I | 1 |
| Nikiphorou, E | 1 |
| Tan, AL | 1 |
| Chatterjee, T | 1 |
| Cavagna, L | 1 |
| Saavedra, MA | 1 |
| Shinjo, SK | 1 |
| Ziade, N | 1 |
| Knitza, J | 1 |
| Kuwana, M | 1 |
| Distler, O | 1 |
| Chinoy, H | 1 |
| Aggarwal, R | 1 |
| Gupta, L | 1 |
| Choi, R | 1 |
| Bhullar, S | 1 |
| Glusac, E | 1 |
| Podoltsev, N | 1 |
| Leventhal, J | 1 |
| Zheng, YQ | 1 |
| Li, HJ | 1 |
| Chen, L | 1 |
| Lin, SP | 1 |
| Liu, Y | 1 |
| Wei, Y | 1 |
| Zhang, Y | 1 |
| Yang, H | 1 |
| Sazgarnia, S | 1 |
| Layegh, P | 1 |
| Darchini-Maragheh, E | 1 |
| Sepehr, V | 1 |
| Meshkat, M | 1 |
| Fathi-Najafi, S | 1 |
| Rahsepar, S | 1 |
| Hawtin, S | 1 |
| André, C | 1 |
| Collignon-Zipfel, G | 1 |
| Appenzeller, S | 1 |
| Bannert, B | 1 |
| Baumgartner, L | 1 |
| Beck, D | 1 |
| Betschart, C | 1 |
| Boulay, T | 1 |
| Brunner, HI | 1 |
| Ceci, M | 1 |
| Deane, J | 1 |
| Feifel, R | 1 |
| Ferrero, E | 1 |
| Kyburz, D | 1 |
| Lafossas, F | 1 |
| Loetscher, P | 1 |
| Merz-Stoeckle, C | 1 |
| Michellys, P | 1 |
| Nuesslein-Hildesheim, B | 1 |
| Raulf, F | 1 |
| Rush, JS | 1 |
| Ruzzante, G | 1 |
| Stein, T | 1 |
| Zaharevitz, S | 1 |
| Wieczorek, G | 1 |
| Siegel, R | 1 |
| Gergely, P | 1 |
| Shisha, T | 1 |
| Junt, T | 1 |
| Yildirim, M | 1 |
| Oluklu, D | 1 |
| Beser, DM | 1 |
| Hendem, DU | 1 |
| Aktas, BA | 1 |
| Yildiz, EG | 1 |
| Kara, O | 1 |
| Sahin, D | 1 |
| Vasilijević, JB | 1 |
| Kovačević, IM | 1 |
| Dijana, R | 1 |
| Dačić, B | 1 |
| Marić, G | 1 |
| Stanojlović, S | 1 |
| Mena-Vázquez, N | 1 |
| Fernández-Nebro, A | 1 |
| Pego-Reigosa, JM | 1 |
| Galindo, M | 1 |
| Melissa-Anzola, A | 1 |
| Uriarte-Isacelay, E | 1 |
| Olivé-Marqués, A | 1 |
| Aurrecoechea, E | 1 |
| Freire, M | 1 |
| Tomero, E | 1 |
| García-Villanueva, MJ | 1 |
| Stoye, C | 1 |
| Salas-Heredia, E | 1 |
| Bernal-Vidal, JA | 2 |
| Salgado, E | 1 |
| Blanco, R | 1 |
| Javier Novoa, F | 1 |
| Ibáñez-Barcelo, M | 1 |
| Torrente-Segarra, V | 1 |
| Narvaez, J | 1 |
| Calvet, J | 1 |
| Moriano Morales, C | 1 |
| Ramon Vazquez-Rodriguez, T | 1 |
| Garcia de la Peña, P | 1 |
| Bohórquez, C | 1 |
| Andreu-Sánchez, JL | 1 |
| Cobo-Ibañez, T | 1 |
| Bonilla, G | 1 |
| Lozano-Rivas, N | 1 |
| Montilla, C | 1 |
| Toyos, FJ | 1 |
| De la Fuente, JLM | 1 |
| Expósito, L | 1 |
| Ruiz-Lucea, ME | 1 |
| Vals, E | 1 |
| Manero-Ruiz, J | 1 |
| Rua-Figueroa, I | 1 |
| Askanase, AD | 1 |
| Khalili, L | 1 |
| Buyon, JP | 2 |
| Emmi, G | 1 |
| Bettiol, A | 1 |
| Mattioli, I | 1 |
| Silvestri, E | 1 |
| Di Scala, G | 1 |
| Urban, ML | 1 |
| Vaglio, A | 1 |
| Prisco, D | 1 |
| Martinez, GP | 1 |
| Zabaleta, ME | 1 |
| Di Giulio, C | 1 |
| Charris, JE | 1 |
| Mijares, MR | 1 |
| Nirk, EL | 1 |
| Reggiori, F | 1 |
| Mauthe, M | 1 |
| Winthrop, KL | 1 |
| Brunton, AE | 1 |
| Beekmann, S | 1 |
| Polgreen, P | 1 |
| Baddley, J | 1 |
| Saag, KG | 1 |
| Calabrese, C | 1 |
| Calabrese, L | 1 |
| Robinson, PC | 1 |
| Wallace, ZS | 1 |
| Curtis, JR | 1 |
| Salvarani, C | 1 |
| Mancuso, P | 1 |
| Gradellini, F | 1 |
| Viani, N | 1 |
| Pandolfi, P | 1 |
| Reta, M | 1 |
| Carrozzi, G | 1 |
| Sandri, G | 1 |
| Bajocchi, G | 1 |
| Galli, E | 1 |
| Muratore, F | 1 |
| Boiardi, L | 1 |
| Pipitone, N | 1 |
| Cassone, G | 1 |
| Croci, S | 1 |
| Marata, AM | 1 |
| Costantini, M | 1 |
| Giorgi Rossi, P | 1 |
| Kabeerdoss, J | 1 |
| Danda, D | 1 |
| Montero, F | 1 |
| Martínez-Barrio, J | 1 |
| Serrano-Benavente, B | 1 |
| González, T | 1 |
| Rivera, J | 1 |
| Molina Collada, J | 1 |
| Castrejón, I | 1 |
| Álvaro-Gracia, J | 1 |
| Hammad, I | 1 |
| Porter, TF | 1 |
| Pothen, L | 1 |
| Yildiz, H | 1 |
| Samnick, MM | 1 |
| Yombi, JC | 1 |
| Chen, RI | 1 |
| Chen, AX | 1 |
| Greenlee, TE | 1 |
| Conti, TF | 1 |
| Deal, C | 1 |
| Singh, RP | 1 |
| Lisney, AR | 1 |
| Szelinski, F | 1 |
| Reiter, K | 1 |
| Burmester, GR | 1 |
| Rose, T | 1 |
| Dörner, T | 1 |
| Gianfrancesco, MA | 1 |
| Schmajuk, G | 1 |
| Haserodt, S | 1 |
| Trupin, L | 1 |
| Izadi, Z | 1 |
| Jafri, K | 1 |
| Shiboski, S | 1 |
| Sirota, M | 1 |
| Yazdany, J | 1 |
| Piscianz, E | 1 |
| Cuzzoni, E | 1 |
| Sharma, R | 1 |
| Tesser, A | 1 |
| Sapra, P | 1 |
| Tommasini, A | 1 |
| Eren, M | 1 |
| Kucukevcilioglu, M | 1 |
| Durukan, AH | 1 |
| Dumas, M | 1 |
| Hua, C | 1 |
| Hotz, C | 1 |
| Velter, C | 1 |
| Duong, TA | 1 |
| Maraffi, T | 1 |
| Ortonne, N | 1 |
| Hüe, S | 1 |
| Fardet, L | 1 |
| de Prost, N | 1 |
| Wolkenstein, P | 1 |
| Ingen-Housz-Oro, S | 1 |
| Chosidow, O | 1 |
| Casian, A | 1 |
| Sangle, SR | 1 |
| D'Cruz, DP | 1 |
| Schreiber, K | 1 |
| Davies, N | 1 |
| Hunt, BJ | 1 |
| Rayess, N | 1 |
| Patel, VR | 1 |
| Zeidi, M | 1 |
| Chansky, PB | 1 |
| Werth, VP | 1 |
| Barsalou, J | 1 |
| Costedoat-Chalumeau, N | 2 |
| Berhanu, A | 1 |
| Fors-Nieves, C | 1 |
| Shah, U | 1 |
| Brown, P | 1 |
| Laskin, CA | 1 |
| Morel, N | 1 |
| Levesque, K | 1 |
| Silverman, ED | 1 |
| Izmirly, PM | 1 |
| Khosa, S | 1 |
| Khanlou, N | 1 |
| Khosa, GS | 1 |
| Mishra, SK | 1 |
| Campochiaro, C | 1 |
| Atay, S | 1 |
| Clark, KEN | 1 |
| Ong, V | 1 |
| Denton, CP | 1 |
| Belfeki, N | 1 |
| Shankarasivam, G | 1 |
| Declerck, D | 1 |
| Diamantis, S | 1 |
| Kumar, AB | 1 |
| Blixt, EK | 1 |
| Drage, LA | 1 |
| El-Azhary, RA | 1 |
| Wetter, DA | 1 |
| Mollerach, FB | 1 |
| Scolnik, M | 1 |
| Catoggio, LJ | 1 |
| Rosa, J | 1 |
| Soriano, ER | 1 |
| Mekinian, A | 1 |
| Masseau, A | 1 |
| Botta, A | 1 |
| Chudzinski, A | 1 |
| Theulin, A | 1 |
| Emmanuelli, V | 1 |
| Hachulla, E | 1 |
| De Carolis, S | 1 |
| Revaux, A | 1 |
| Nicaise, P | 1 |
| Cornelis, F | 1 |
| Subtil, D | 1 |
| Montestruc, F | 1 |
| Bucourt, M | 1 |
| Chollet-Martin, S | 1 |
| Carbillon, L | 1 |
| Fain, O | 1 |
| Palazzi, C | 1 |
| D'Amico, E | 1 |
| D'Angelo, S | 1 |
| Gilio, M | 1 |
| Leccese, P | 1 |
| Olivieri, I | 1 |
| Geamănu Pancă, A | 1 |
| Popa-Cherecheanu, A | 1 |
| Marinescu, B | 1 |
| Geamănu, CD | 1 |
| Voinea, LM | 1 |
| Kaplan, YC | 1 |
| Ozsarfati, J | 1 |
| Nickel, C | 1 |
| Koren, G | 1 |
| Danza, Á | 1 |
| Graña, D | 1 |
| Goñi, M | 1 |
| Vargas, A | 1 |
| Ruiz-Irastorza, G | 1 |
| Ferreira, CS | 1 |
| Beato, J | 1 |
| Falcão, MS | 1 |
| Brandão, E | 1 |
| Falcão-Reis, F | 1 |
| Carneiro, ÂM | 1 |
| Francès, C | 1 |
| Meyer, KC | 1 |
| Decker, C | 1 |
| Baughman, R | 1 |
| Rozin, AP | 1 |
| Egozi, D | 1 |
| Ramon, Y | 1 |
| Toledano, K | 1 |
| Braun-Moscovici, Y | 1 |
| Markovits, D | 1 |
| Schapira, D | 1 |
| Bergman, R | 1 |
| Melamed, Y | 1 |
| Ullman, Y | 1 |
| Balbir-Gurman, A | 1 |
| Ben-Zvi, I | 1 |
| Kivity, S | 1 |
| Langevitz, P | 1 |
| Shoenfeld, Y | 1 |
| RUGGIERO, HA | 1 |
| Reeves, GE | 1 |
| Boyle, MJ | 1 |
| Bonfield, J | 1 |
| Dobson, P | 1 |
| Loewenthal, M | 1 |
| Cimaz, R | 2 |
| Meregalli, E | 2 |
| Biggioggero, M | 1 |
| Borghi, O | 1 |
| Tincani, A | 2 |
| Motta, M | 2 |
| Airò, P | 1 |
| Meroni, PL | 1 |
| Brucato, A | 1 |
| Muscará, M | 1 |
| Sergi, P | 1 |
| Jiménez-Alonso, J | 1 |
| Sabio, JM | 1 |
| Carrillo-Alascio, PL | 1 |
| Jiménez-Jáimez, J | 1 |
| Ortego-Centeno, N | 1 |
| Jiménez-Jáimez, E | 1 |
| Hidalgo-Tenorio, C | 1 |
| Guzmán-Ubeda, M | 1 |
| Jáimez, L | 1 |
| Cáliz, R | 1 |
| García-Sánchez, A | 1 |
| Gallego, M | 1 |
| Caminal, L | 1 |
| Callejas-Rubio, JL | 1 |
| Cervera, R | 1 |
| Font, J | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Thomson, JC | 1 |
| Knight, AK | 1 |
| Cunningham-Rundles, C | 1 |
| Wang, Y | 1 |
| Yan, T | 1 |
| Shen, J | 1 |
| Guo, H | 1 |
| Xiang, X | 1 |
| Ciardelli, L | 1 |
| Marconi, M | 1 |
| Gasparoni, A | 1 |
| Lojacono, A | 1 |
| Chirico, G | 1 |
| Lyons, JS | 1 |
| Severns, ML | 1 |
| Pinckers, A | 1 |
| Broekhuyse, RM | 1 |
| Senécal, JL | 1 |
| Chartier, S | 1 |
| Rothfield, N | 1 |
| Van Horn, G | 1 |
| Arnett, FC | 1 |
| Dimachkie, MM | 1 |
| Fox, R | 1 |
| Wallace, DJ | 1 |
| Jones, BR | 1 |
| Voop, HV | 1 |
| Rekant, SI | 1 |
| Becker, LE | 1 |
| Clauvel, JP | 1 |
| Seligmann, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS[NCT04754698] | Phase 4 | 2,067 participants (Anticipated) | Interventional | 2021-02-09 | Active, not recruiting | ||
| Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study[NCT04341441] | Phase 3 | 624 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.) | ||
| Hydroxychloroquine Efficacy in Chronic Urticaria[NCT01073852] | 0 participants (Actual) | Interventional | 2011-06-30 | Withdrawn (stopped due to withdrawn, not funded) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
| Non-Randomized Active Comparator | 0 |
Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 2 |
Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Correlation coefficient (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks
| Intervention | Inflammatory markers (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 1 |
| Study Drug - Weekly Dose | 1 |
| Placebo | 1 |
| Non-Randomized Active Comparator | 0 |
Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Clinical factors (Number) |
|---|---|
| Study Drug - Daily Dose | NA |
| Study Drug - Weekly Dose | NA |
| Placebo | NA |
| Non-Randomized Active Comparator | NA |
Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Drug - Daily Dose | 0 |
| Study Drug - Weekly Dose | 0 |
| Placebo | 0 |
| Non-Randomized Active Comparator | 0 |
Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks
| Intervention | Number of adverse events. (Number) | |
|---|---|---|
| Adverse events (only Level 1 and 2) observed in the study. | Serious adverse events (Level 3 or 4). | |
| Non-Randomized Active Comparator | 2 | 0 |
| Placebo | 188 | 0 |
| Study Drug - Daily Dose | 206 | 0 |
| Study Drug - Weekly Dose | 193 | 0 |
20 reviews available for hydroxychloroquine and Autoimmune Diseases
| Article | Year |
|---|---|
Small molecules targeting cGAS-STING pathway for autoimmune disease.
Topics: Autoimmune Diseases; Humans; Inflammation; Membrane Proteins; Nucleotidyltransferases; Signal Transd | 2022 |
Clinical and immunological features of chronic ulcerative stomatitis: A systematic review.
Topics: Animals; Autoimmune Diseases; Chronic Disease; Female; Fluorescent Antibody Technique, Indirect; Gin | 2022 |
Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis.
Topics: Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; Hypertension, Pregnan | 2023 |
SARS-CoV-2 infection among patients with systemic autoimmune diseases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Autoi | 2020 |
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Topics: Autoimmune Diseases; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hydroxy | 2020 |
Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythemat | 2020 |
Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Topics: Antibodies, Antiphospholipid; Antirheumatic Agents; Antiviral Agents; Autoimmune Diseases; COVID-19; | 2020 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani | 2020 |
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
Topics: Antiviral Agents; Autoimmune Diseases; Cardiotoxicity; COVID-19 Drug Treatment; Humans; Hydroxychlor | 2021 |
Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs.
Topics: Antimalarials; Autoimmune Diseases; Humans; Hydroxychloroquine; Interferon Type I; Lupus Erythematos | 2018 |
New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis.
Topics: Autoimmune Diseases; Humans; Hydroxychloroquine; Immunologic Factors; Systemic Vasculitis | 2018 |
An update on the management of hepatitis C virus-related arthritis.
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis; Autoimmune Diseases; Cyclosporine; Disease Manage | 2014 |
Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.
Topics: Autoimmune Diseases; Humans; Hydroxychloroquine; Incidence; Macular Degeneration; Risk Factors | 2014 |
Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Antirheumatic Agents; Autoimmune Diseases; Female; Humans; Hydroxychloroquine | 2016 |
[Hydroxychloroquine for autoimmune diseases].
Topics: Autoimmune Diseases; Humans; Hydroxychloroquine; Immunologic Factors | 2016 |
Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimetabolites; Autoimmune Diseases; Benzamides; C | 2010 |
Hydroxychloroquine: from malaria to autoimmunity.
Topics: Animals; Anti-Inflammatory Agents; Antigen Presentation; Antimalarials; Autoimmune Diseases; Autoimm | 2012 |
Inflammatory and autoimmune complications of common variable immune deficiency.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.
Topics: Antigen Presentation; Antimalarials; Autoantigens; Autoimmune Diseases; Chloroquine; Drug Design; Hi | 1996 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Topics: Antimalarials; Antiphospholipid Syndrome; Autoimmune Diseases; Chloroquine; Controlled Clinical Tria | 1996 |
2 trials available for hydroxychloroquine and Autoimmune Diseases
| Article | Year |
|---|---|
Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation.
Topics: Adult; Autoimmune Diseases; Chronic Disease; Dermatologic Agents; Female; Humans; Hydroxychloroquine | 2004 |
[Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions].
Topics: Adult; Advertising; Antimalarials; Autoimmune Diseases; Female; Humans; Hydroxychloroquine; Lupus Er | 2004 |
44 other studies available for hydroxychloroquine and Autoimmune Diseases
| Article | Year |
|---|---|
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.
Topics: Adult; Animals; Autoimmune Diseases; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Exanthema; Female; | 2022 |
Treatment of myelodysplasia-associated reactive, non-interstitial granulomatous dermatitis with hydroxychloroquine.
Topics: Autoimmune Diseases; Dermatitis; Granuloma; Humans; Hydroxychloroquine | 2023 |
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Topics: Antibodies, Viral; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Imm | 2022 |
A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo.
Topics: Adolescent; Adult; Autoimmune Diseases; Female; Humans; Hydroxychloroquine; Male; Treatment Outcome; | 2022 |
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.
Topics: Animals; Autoimmune Diseases; Humans; Hydroxychloroquine; Interferons; Lupus Erythematosus, Systemic | 2023 |
The assessment of fetal cardiac functions in pregnancies with autoimmune diseases: a prospective case-control study.
Topics: Autoimmune Diseases; Case-Control Studies; Echocardiography, Doppler; Female; Fetal Heart; Humans; H | 2023 |
Optical coherence tomography angiography parameters in patients taking hydroxychloroquine therapy.
Topics: Autoimmune Diseases; Cross-Sectional Studies; Fluorescein Angiography; Humans; Hydroxychloroquine; R | 2023 |
Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.
Topics: Adult; Antirheumatic Agents; Autoimmune Diseases; Autoimmunity; Cross-Sectional Studies; Female; Hum | 2020 |
Thoughts on COVID-19 and autoimmune diseases.
Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Co | 2020 |
SARS CoV-2 infection among patients using immunomodulatory therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized | 2021 |
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, | 2021 |
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agen | 2020 |
Hydroxychloroquine Prescription Practices after 2016 American Academy of Ophthalmology Recommendations.
Topics: Academies and Institutes; Antirheumatic Agents; Autoimmune Diseases; Drug Prescriptions; Female; Fol | 2021 |
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Che | 2017 |
Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Autoimmune Diseases; Female; Human | 2017 |
Macular sensitivities measured by microperimetry in patients on hydroxychloroquine treatment.
Topics: Adult; Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychlor | 2018 |
Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that 'toxic' epidermal necrolysis can be 'non-toxic'.
Topics: Antibodies, Antinuclear; Autoimmune Diseases; Cyclophosphamide; Fatal Outcome; Female; Humans; Hydro | 2018 |
Using hydroxychloroquine and protecting the retina.
Topics: Antirheumatic Agents; Autoimmune Diseases; Electroretinography; Humans; Hydroxychloroquine; Retinal | 2018 |
Bilateral Severe Decreased Vision With Normal Examination Findings.
Topics: Adult; Antibiotics, Antineoplastic; Antirheumatic Agents; Autoimmune Diseases; Cataract; Cystic Fibr | 2018 |
Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings.
Topics: Acute Disease; Autoantibodies; Autoimmune Diseases; Dermatomyositis; Dietary Supplements; Humans; Hy | 2019 |
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
Topics: Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; | 2018 |
Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities.
Topics: Aged; Antirheumatic Agents; Autoimmune Diseases; Autophagy; Female; Humans; Hydroxychloroquine; Male | 2018 |
Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency.
Topics: Adult; Aftercare; Antirheumatic Agents; Autoimmune Diseases; Humans; Hydroxychloroquine; Iloprost; I | 2019 |
Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Antirheumatic Agents; Autoimmune Disease | 2019 |
Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.
Topics: Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Child; Deglutition Disorders; Drug Eva | 2019 |
Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies.
Topics: Adult; Antibodies, Antinuclear; Argentina; Atrioventricular Block; Autoimmune Diseases; Autoimmunity | 2019 |
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi | 2015 |
CHOROIDAL THICKNESS IN MULTISYSTEMIC AUTOIMMUNE DISEASES WITHOUT OPHTHALMOLOGIC MANIFESTATIONS.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Choroid; Cross-Sectional St | 2017 |
[What's new in internal medicine?].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Bacteriophages; Body Mass | 2008 |
Large leg ulcers due to autoimmune diseases.
Topics: Animals; Antibodies, Monoclonal; Autoimmune Diseases; Azathioprine; Ciprofloxacin; Cyclophosphamide; | 2011 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy.
Topics: Adult; Aspirin; Autoimmune Diseases; Azathioprine; Cyclosporine; Dexamethasone; Female; Hemoglobins; | 2004 |
Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al.
Topics: Autoimmune Diseases; Breast Feeding; Child, Preschool; Electroretinography; Female; Humans; Hydroxyc | 2004 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Chronic inflammation of the vagina: treatment and relationship to autoimmunity.
Topics: Adolescent; Adult; Antirheumatic Agents; Autoimmune Diseases; Chronic Disease; Dyspareunia; Endometr | 2005 |
Preventive effect of Ophiopogon japonicus polysaccharides on an autoallergic mouse model for Sjogren's syndrome by regulating the Th1/Th2 cytokine imbalance.
Topics: Animals; Autoantigens; Autoimmune Diseases; Body Weight; Cytokines; Disease Models, Animal; Drinking | 2007 |
Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents.
Topics: Autoimmune Diseases; Azathioprine; Cyclosporine; Female; Humans; Hydroxychloroquine; Immune System; | 2007 |
Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Autoimmune Diseases; Child; Dose-R | 2009 |
The EOG in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Electrooculography; Female; Humans; H | 1983 |
Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1995 |
Reversible dementia and chorea in a young woman with the lupus anticoagulant.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Autoimmune Diseases; Chorea; Dementia; Depression; Diagno | 1996 |
The management of keratoconjuctivitis sicca.
Topics: Anesthetics; Autoimmune Diseases; Bicarbonates; Chloramphenicol; Cysteine; Dextrans; Heparin; Herpes | 1965 |
Auto-immune annular erythema. A variant of lupus erythematosus?
Topics: Antibodies, Antinuclear; Autoimmune Diseases; Biopsy; Blood Protein Electrophoresis; Complement Fixa | 1973 |
[Primary hyperimmunoglobulinemic purpura].
Topics: Adolescent; Adult; Aged; Antibodies; Autoimmune Diseases; Chloramphenicol; Female; Humans; Hydroxych | 1971 |